Last checked at 25 Apr 2016 08:48
Director Dealings / Market Share Purchase
Oxford, UK - 25 April 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Friday 22 April 2016 acquired ordinary shares in the Group as set out below, under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.
|
|
|
| Interest after purchase | |
Director / PDMR | Title | Price per share (p) | Number of Ordinary Shares acquired | Number of Ordinary Shares | % of total issued share capital |
Dr Lorenzo Tallarigo | Chairman | 6.425p | 41,083 | 119,003 | 0.004% |
The issued share capital of the Group is 2,702,864,994 ordinary 1p shares.
-Ends-
For further information, please contact: |
|
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer |
Tel: +44 (0)1865 783 000 |
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton |
Tel: +44 (0)20 3709 5700 |
Notes to editors
Oxford BioMedica®
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk